Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase 2 Recruiting 20 enrolled ImmunityBio, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Timeline

Start: 2025-11-11
Primary completion: 2027-05-25
Completion: 2028-05-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 t-haNK	Cell therapy	—	Intravenous

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications